轻度创伤性脑损伤的靶向多域治疗:一项随机临床试验
这项多中心随机临床试验在2家脑震荡专科门诊开展,纳入18至49岁、距轻度创伤性脑损伤8天至6个月的患者162例(每组81例),随机接受按各域定制的靶向多域干预或行为管理对照,干预4周、随访3个月。主要终点从基线至4周的NSI症状严重度变化组间无显著差异(aMD -0.5,95%CI -3.6至2.6,P=.98),PGIC感知改善的OR为1.18(95%CI 0.46-3.04,P=.21)。敏感性分析中靶向多域组在总分、眼动、前庭症状及多项前庭-眼动指标和认知处理速度上改善更明显。10例(6%)报告不良事件。
要点
- 主要终点未达显著:4周NSI症状严重度靶向多域组与对照组aMD -0.5(95%CI -3.6至2.6,P=.98),PGIC的OR 1.18(95%CI 0.46-3.04,P=.21)。
- 敏感性分析中靶向多域组总分改善更明显(aMD -4.0,95%CI -7.6至-0.5,P=.045),眼动(aMD -0.9,95%CI -1.7至-0.1,P=.02)与前庭症状(aMD -0.8,95%CI -1.5至-0.2,P=.01)亦更优。
- 前庭-眼动汇聚(aMD -1.8,95%CI -3.2至-0.3,P=.046)、水平前庭-眼反射(aMD -1.8,95%CI -3.2至-0.3,P=.02)、垂直前庭-眼反射(aMD -2.2,95%CI -3.8至-0.7,P=.01)和视觉运动敏感度(aMD -2.2,95%CI -4.0至-0.7,P=.01)在靶向多域组改善更明显。
- 认知处理速度在靶向多域组改善更明显(aMD 2.4,95%CI 0.6至4.2,P=.04)。
- 10例(6%)报告不良事件;作者认为这些发现可为mTBI提供更有效、高效且基于证据的照护方式。
适用人群与场景
- 18至49岁、距轻度创伤性脑损伤8天至6个月的成人,在2家脑震荡专科门诊纳入。
处置流程与药物剂量
- 靶向多域干预按焦虑与情绪、认知、偏头痛与头痛、眼动、前庭、睡眠和自主神经各域定制,干预4周,随访3个月。
- 对照组接受行为管理。
研究设计与关键结果
- 多中心随机临床试验,2家脑震荡专科门诊,2021年6月至2024年4月,筛查1639例、符合745例、随机162例(每组81例;女102例[63%],男60例[37%];平均[SD]年龄29[8]岁),干预4周、随访3个月。
- 主要终点从基线至4周:NSI症状严重度aMD -0.5(95%CI -3.6至2.6,P=.98),PGIC感知改善OR 1.18(95%CI 0.46-3.04,P=.21),两组相似。
- 敏感性分析:靶向多域组总分aMD -4.0(95%CI -7.6至-0.5,P=.045)、眼动aMD -0.9(95%CI -1.7至-0.1,P=.02)、前庭aMD -0.8(95%CI -1.5至-0.2,P=.01)改善更明显。
- 敏感性分析:前庭与眼动汇聚aMD -1.8(95%CI -3.2至-0.3,P=.046)、水平前庭-眼反射aMD -1.8(95%CI -3.2至-0.3,P=.02)、垂直前庭-眼反射aMD -2.2(95%CI -3.8至-0.7,P=.01)、视觉运动敏感度aMD -2.2(95%CI -4.0至-0.7,P=.01)改善更明显。
- 敏感性分析:认知处理速度aMD 2.4(95%CI 0.6至4.2,P=.04),靶向多域组更优。
- 不良事件:10例(6%)报告不良事件。
证据类型、等级与局限
- 证据类型:多中心随机临床试验(RCT),注册号NCT04549532。
- 作者结论:mTBI症状和患者感知改善在靶向多域组与对照组相似;这些发现可为更有效、高效且基于证据的mTBI照护提供信息。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现可为mTBI提供更有效、高效且基于证据的照护方式。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Mild traumatic brain injuries (mTBI) involving anxiety and mood, cognitive, migraine and headache, ocular, vestibular, sleep, and autonomic domains can result in chronic symptoms and impairments, thereby increasing morbidity and decreasing quality of life for patients. Timely interventions targeting involved mTBI domains may improve symptoms and impairments and accelerate recovery.
OBJECTIVE: To evaluate the effectiveness of a targeted multidomain (T-MD) intervention for mTBI in adults.
DESIGN, SETTING, AND PARTICIPANTS: This multisite randomized clinical trial (RCT), conducted at 2 specialty concussion clinics from June 2021 to April 2024, involved a 4-week intervention and a total follow-up duration of 3 months. Participants were aged 18 to 49 years and were within 8 days to 6 months of an mTBI.
INTERVENTION: Patients were randomized to T-MD interventions tailored to each domain or a behavioral management control group (control).
MAIN OUTCOMES AND MEASURES: Primary outcomes included changes in the Neurobehavioral Symptom Inventory (NSI) and Patient Global Impression of Change (PGIC) assessed from baseline to 4 weeks. Secondary outcomes included domain-specific symptoms and impairments and adverse events. Least-squares adjusted mean differences (aMDs) and 95% CIs were calculated to assess differences between groups.
RESULTS: Of 1639 patients screened, 745 were eligible and 162 (81 per group) were randomized to T-MD or control (102 female [63%]; 60 male [37%]; mean [SD] age, 29 [8] years). The 2 groups experienced similar improvements over time in NSI symptom severity (aMD, -0.5; 95% CI, -3.6 to 2.6; P = .98) and perceived improvement on the PGIC (odds ratio, 1.18; 95% CI, 0.46-3.04; P = .21). In sensitivity analyses, the T-MD group experienced greater improvement in total (aMD, -4.0; 95% CI, -7.6 to -0.5; P = .045), ocular (aMD, -0.9; 95% CI, -1.7 to -0.1; P = .02), and vestibular (aMD, -0.8; 95% CI, -1.5 to -0.2; P = .01) symptoms; vestibular and ocular motor convergence (aMD, -1.8; 95% CI, -3.2 to -0.3; P = .046); horizontal vestibulo-ocular reflex (aMD, -1.8; 95% CI, -3.2 to -0.3; P = .02); vertical vestibulo-ocular reflex (aMD, -2.2; 95% CI, -3.8 to -0.7; P = .01); visual motion sensitivity (aMD, -2.2; 95% CI, -4.0 to -0.7; P = .01); and cognitive processing speed (aMD, 2.4; 95% CI, 0.6 to 4.2; P = .04). Adverse events were reported by 10 participants (6%).
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, mTBI symptoms and patients' perception of change improved similarly for the T-MD and control groups. These findings can inform a more effective, efficient, and evidence-based approach to care for mTBI.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04549532.
参考来源
- Kontos AP, Collins MW, Okonkwo DO, et al. Targeted Multidomain Treatment for Mild Traumatic Brain Injury: A Randomized Clinical Trial. JAMA Netw Open. 2026. PMID: 41817527. doi:10.1001/jamanetworkopen.2026.1317
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。